Amanda Leach

发表

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom

P. Beutels, T. Heikkinen, C. Giaquinto, 2021, The Journal of infectious diseases.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis

R. Mikolajczyk, T. Heikkinen, C. Giaquinto, 2022, Journal of global health.

Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings

S. Madhi, S. Stoszek, J. Langley, 2022, The Journal of infectious diseases.

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

S. Madhi, H. Zar, M. P. Griffin, 2023, The Lancet. Child & adolescent health.

Follow‐up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66

K. Bojang, U. d’Alessandro, B. Greenwood, 1997, Parasite immunology.

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age

Andrea A. Berry, N. Chiu, J. Langley, 2022, The Journal of infectious diseases.

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.

S. Madhi, M. P. Griffin, E. Simões, 2022, The New England journal of medicine.

Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children

S. Madhi, S. Stoszek, J. Langley, 2023, Journal of the Pediatric Infectious Diseases Society.

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

A. Aksyuk, M. Esser, T. Villafana, 2023, Nature Medicine.

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.

S. Madhi, L. Hammitt, R. Dagan, 2023, The New England journal of medicine.

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Johnathan D. Guest, A. M. Stanley, S. Madhi, 2023, Nature communications.

Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants.

B. Greenwood, A. Leach, S. Ceesay, 1996, The Pediatric infectious disease journal.